Affiliations 

  • 1 Faculty of Science and Marine Environment, Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia
  • 2 School of Biological Sciences, Universiti Sains Malaysia, 11800, Penang, Malaysia; Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm), NIBM, 11700, Penang, Malaysia; Centre for Chemical Biology, Universiti Sains Malaysia, Bayan Lepas, 11900, Penang, Malaysia
  • 3 Faculty of Fisheries and Food Sciences, Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia
  • 4 Faculty of Science and Marine Environment, Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia; Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm), NIBM, 11700, Penang, Malaysia; Institute of Marine Biotechnology (IMB), Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia. Electronic address: kesaven@umt.edu.my
Biologicals, 2021 Jun;71:51-54.
PMID: 33858743 DOI: 10.1016/j.biologicals.2021.03.002

Abstract

A natural biodegradable polymer, polyhydroxyalkanoate (PHA), was adjuvanted with a vaccine seed to observe the biomaterial's ability in enhancing an immune response in rats. The adjuvant potential of PHA was tested using the whole-killed Pasteurella multocida B:2 (PMB2) vaccine in Sprague Dawley (SD) rats to detect changes in serum immunoglobulin G (IgG) and immunoglobulin M (IgM) responses. A common PHA, poly(3-hydroxybutyrate) [P(3HB)], from Bacillus megaterium UMTKB-1 was constructed into microparticles using the solvent evaporation method. Twelve SD rats were divided into four treatment groups: 1) non-treatment as negative control, 2) P(3HB) adjuvant, 3) PMB2 vaccine, and 4) adjuvanted-P(3HB)/PMB2 vaccine groups, which were intramuscularly vaccinated twice. Immunoglobulins IgG and IgM levels were used as markers of the immune response induced by the adjuvanted-P(3HB)/PMB2 vaccine and analysed over an eight-week study period. The group vaccinated specifically with adjuvanted-P(3HB)/PMB2 vaccine had higher concentrations of immunoglobulins compared to other treatment groups, hence demonstrating the potential of the adjuvant to enhance immune response. Findings showed a need to delay the delivery of the second booster dose to determine the appropriate regime for the adjuvanted-P(3HB)/PMB2 vaccine.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.